title: [The goal is: fewer side effects, better compliance (interview by Wolfgang van den Bergh, Michael Hubert and Helmut Laschet)].
authors.forename: Kai
authors.initials: K
authors.lastname: Martens
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D058006:General Practice; D005858:Germany; D006301:Health Services Needs and Demand; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D010166:Palliative Care; D010636:Phenols / Q000009:adverse effects / Q000627:therapeutic use*; D000077432:Tapentadol
chemical_list: D000701:Analgesics, Opioid; D010636:Phenols; D000077432:Tapentadol